Resources

Japanese encephalitis (JE), spread by infected mosquitoes, is the leading cause of viral encephalitis in Asia. Myanmar is among Asia’s JE-endemic countries due to its ecological environment, including widespread rice farming, which is conducive to JE transmission.PATH played a significant role in advocating for the introduction of the JE vaccine in Myanmar, providing support to the Ministry of Health and Sports to discuss opportunities for JE control. PATH provided technical assistance to Myanmar’s central Expanded Programme on Immunization (cEPI) in the country’s first immunization campaign against JE, and the subsequent integration of the JE vaccine into national routine immunization.Myanmar’s nationwide immunization campaign against Japanese encephalitis reached more than 12 million children, covering 92.5 percent of the country.PATH also extended its support to cEPI to conduct an evaluation of JE vaccine introduction in the first quarter of 2019.

This report describes the key takeaways from PATH's Advocacy Learning Lab on decentralization held in Nairobi, Kenya in February 2019. This Learning Lab convened 125 attendees from seven African countries—Kenya, Uganda, Zambia, Malawi, Democratic Republic of the Congo, Nigeria, and Senegal.PATH's Advocacy Learning Lab series aims to provide an opportunity for advocates, health practitioners, policy makers, data experts, and funders together to share learnings and experiences from their work on health policy and implementation. The interactive Learning Lab features a mix of sessions to impart knowledge, promote exchange of ideas, and facilitate action planning and applied learning both across countries and through deep-dives into individual country contexts.

This brief presents findings from the Global Fund Prospective Country Evaluation (PCE) in the Democratic Republic of the Congo (DRC) assessing the role and function of partnerships in the 2017 Global Fund application process. The PCE is an independent evaluation of the Global Fund commissioned by the Global Fund's Technical Evaluation Reference Group (TERG). The PCE is designed to evaluate how Global Fund policies and processes play out in country and provide high quality, actionable, timely information to national program implementers and Global Fund policymakers.

This fact sheet describes a PATH project in Vietnam that is focusing on testing a new formulation of a locally made rotavirus vaccine. PATH, Vietnam-based manufacturer POLYVAC (Center for Research and Production of Vaccines and Biologicals), and Vietnam’s National Institute of Hygiene and Epidemiology are conducting a Phase 3 bridging study to compare a second-generation formulation of POLYVAC’s new liquid rotavirus vaccine (ROTAVIN) with the currently licensed version (ROTAVIN-M1). Both contain the same rotavirus strain, but ROTAVIN is stored at 2-8°C, while ROTAVIN-M1 must be kept frozen. ROTAVIN would therefore be more compatible with the cold chain currently in place in Vietnam, allowing for easier storage and transport. In the future, it could also be more attractive for use in other low- to middle-income settings.

Subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) is all-in-one injectable contraceptive that protects against pregnancy for three months. PATH regularly hosts webinars to share the latest evidence and experience from DMPA-SC research, introduction, and scale-up, including self-injection.For more information, visit www.path.org/dmpa-sc, sign up for our newsletter, or email FPoptions@path.org.